Dan Eldar
Executive Director @ Longliv Ventures
Dan Eldar is a seed investor at Longliv Ventures focused on Health Care and Wellness. Dan Eldar
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Dan Eldar invests in
Stages Dan Eldar invests in
Countries Dan Eldar invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (67%)
- Wellness 2 (33%)
- Medical Device 2 (33%)
- B2B 1 (17%)
- Medical 1 (17%)
Stage
- Seed 1 (17%)
- Series A 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
Country
- Israel 2 (33%)
- Canada 1 (17%)
- United States 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Empowering the self-care revolution, ApoWiser brings personalized guidance to the online world of Over-The-Counter (OTC) pharmaceuticals - from OTC medications to vitamins, minerals, and supplements (VMS). Navigating the often overwhelming online marketplace, our advanced Business Intelligence (BI) system delivers science-based, individualizedrecommendations, filling a crucial gap in the industry.Considering unique factors such as age, health conditions, and the latest validated information, ApoWiser offers consumers a tailored shopping journey, guiding them towards the OTC and VMS products that best match their needs and lifestyle.Already integrated into the platforms of leading health providers and pharmacy chains like Super-pharm, Superdrug, and Maccabi healthcare services, ApoWiser has tripled conversion rates and significantly boosted consumer engagement over the past two years. As the global OTC pharmaceuticals market continues to grow, ApoWiser stands ready to redefine digital self-care. Step into the future of personalized healthcare with ApoWiser - your trusted partner in the digital self-care revolution. | $1.5M / Seed / Jun 21, 2022 | ||
| AceAge is a healthcare technology company, creating intuitive products to ease the aging process and improve health outcomes.AceAge is the company behind the next innovation in healthcare technology. Its upcoming product is a home health appliance designed to help people take their medication properly. Karie is a personal health companion thatorganizes, schedules, and dispenses pills with easy one-button control. The CEO of AceAge, Spencer Waugh, created Karie to increase the health and safety of medical patients, and as a way to minimize the negative consequences of missed medications or general failure to adhere to medication directions. The success of medicine is dependent on the patient’s compliance with the medical directions that accompany it, making it an integral part of healthcare. The total direct and indirect costs of nonadherence in the US annually is $290 billion. By making daily medicine routines completely automated, Karie removes the chance of human error. Karie uses common multi-dose pouch packaging that can be pre-set by pharmacists. Doses are scheduled, delivered and monitored for the user. Karie is easy to use, enables greater patient autonomy and ensures better healthcare through a highly coordinated program. | $3.9M / Series A / Dec 03, 2020 | ||
| Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s firstproduct, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US. | $71M / Series D / Aug 05, 2020 | ||
| DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD. DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowingwhat food “works” for each person is crucial to an effective care plan. DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight. DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members. | $5M / Series B / Oct 06, 2019 | ||
| DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD. DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowingwhat food “works” for each person is crucial to an effective care plan. DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight. DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members. | $31M / Series B / Jun 26, 2019 | ||
| Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s firstproduct, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US. | $27.8M / Series C / Feb 14, 2019 |
Co-Investors
About Longliv Ventures
Targeting early stage companies with the intent uncover and nourish Consumer Digital Health solutions that will augment and eventually revolutionize the way people manage their health and wellness. Such solutions – that converge healthcare with the world of retail - could benefit from the Group’s global footprint, e.g. 14,500 retail stores in 24markets
Longliv Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Gordon
Head of Digital Health Investments
|
|||
|
Dan Eldar
Executive Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dan Eldar invest in?
Dan Eldar invests primarily in Health Care, Wellness and Medical Device startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dan Eldar?
Public channels for Dan Eldar include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dan Eldar last invest?
The most recent investment recorded for Dan Eldar closed in Jun 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
